Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous adipose-derived stem cells (ADSCs) are a population of multipotent mesenchymal stem cells derived from fat tissue, currently being investigated by Xuzhou Medical University for facial rejuvenation and the treatment of skin aging. The therapy involves harvesting a patient's own fat cells via liposuction, isolating the stem cell fraction, and injecting them into specific facial areas. ADSCs are thought to exert their effects through paracrine mechanisms, secreting various growth factors and cytokines that stimulate resident dermal fibroblasts to produce collagen and elastin. This process aims to restore the dermal microenvironment, improve skin texture, and reduce the visible signs of aging by enhancing tissue regeneration and angiogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Adipose-derived stem cells (Xuzhou Medical University).